Colorectal Cancer (CRC)

Oncology·MeSH: Stomach Neoplasms

Prevalence

135.0 / 100K

Incidence

36.0 / 100K/yr

6 drugs in development·6 companies·23 clinical trials

Drug Pipeline by Phase

Approved(1)

Drug	Company
krazati	BRISTOL MYERS SQUIBB CO (BMY)

Phase 3(2)

Drug	Company
Drug	Summit Therapeutics Inc. (SMMT)
Fruquintinib Combined With Chemotherapy	IGM Biosciences, Inc. (IGMS)

Phase 2(1)

Drug	Company
Vincristine Sulfate Liposome	ENANTA PHARMACEUTICALS INC (ENTA)

Phase 1(2)

Drug	Company
panitumumab	AMGEN INC (AMGN)
varsetatug masetecan	CytomX Therapeutics, Inc. (CTMX)

BioSniper tracks 6 drugs in development for Colorectal Cancer (CRC) across 6 companies.

There are 23 clinical trials targeting Colorectal Cancer (CRC) tracked by BioSniper.

The estimated prevalence of Colorectal Cancer (CRC) is approximately 135.0 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.